JP2007535496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535496A5 JP2007535496A5 JP2007500818A JP2007500818A JP2007535496A5 JP 2007535496 A5 JP2007535496 A5 JP 2007535496A5 JP 2007500818 A JP2007500818 A JP 2007500818A JP 2007500818 A JP2007500818 A JP 2007500818A JP 2007535496 A5 JP2007535496 A5 JP 2007535496A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- composition
- alkyl
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 46
- 239000000203 mixture Substances 0.000 claims 19
- 241000711549 Hepacivirus C Species 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229940079322 interferon Drugs 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 102000014150 Interferons Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 5
- 239000004365 Protease Substances 0.000 claims 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 239000003443 antiviral agent Substances 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- -1 heteroalkenyl Chemical group 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 101100240520 Caenorhabditis elegans nhr-14 gene Proteins 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 229930194542 Keto Natural products 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005281 alkyl ureido group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54825104P | 2004-02-27 | 2004-02-27 | |
| US60/548,251 | 2004-02-27 | ||
| PCT/US2005/006502 WO2005085275A1 (en) | 2004-02-27 | 2005-02-24 | Inhibitors of hepatitis c virus ns3 protease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007535496A JP2007535496A (ja) | 2007-12-06 |
| JP2007535496A5 true JP2007535496A5 (https=) | 2008-03-27 |
| JP4745327B2 JP4745327B2 (ja) | 2011-08-10 |
Family
ID=34919341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500818A Expired - Fee Related JP4745327B2 (ja) | 2004-02-27 | 2005-02-24 | Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7205330B2 (https=) |
| EP (1) | EP1730165A1 (https=) |
| JP (1) | JP4745327B2 (https=) |
| KR (1) | KR20060124725A (https=) |
| CN (1) | CN1950393A (https=) |
| AR (1) | AR047901A1 (https=) |
| AU (1) | AU2005219859A1 (https=) |
| CA (1) | CA2557322A1 (https=) |
| IL (1) | IL177503A0 (https=) |
| TW (1) | TW200536528A (https=) |
| WO (1) | WO2005085275A1 (https=) |
| ZA (1) | ZA200607134B (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100509388B1 (ko) | 1996-10-18 | 2005-08-23 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제 |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| AU2006243000B2 (en) * | 2005-05-05 | 2011-05-26 | Macrophage Pharma Limited | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| NZ563365A (en) * | 2005-06-02 | 2011-02-25 | Schering Corp | Combination of HCV protease inhibitors with a surfactant |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
| US20060281689A1 (en) * | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| AU2006252623A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis C virus |
| AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| AU2006301966A1 (en) | 2005-10-11 | 2007-04-19 | Array Biopharma, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| AR056805A1 (es) * | 2005-11-14 | 2007-10-24 | Schering Corp | Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP2007789B1 (en) | 2006-04-11 | 2015-05-20 | Novartis AG | Spirocyclic HCV/HIV inhibitors and their uses |
| WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| JP2010500978A (ja) | 2006-08-17 | 2010-01-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
| CA2673111A1 (en) | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
| US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
| EP2119702A4 (en) | 2007-01-31 | 2010-12-08 | Dainippon Sumitomo Pharma Co | amide derivative |
| EP2160392A2 (en) * | 2007-05-03 | 2010-03-10 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| WO2008141227A1 (en) * | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| CA2693997C (en) | 2007-08-03 | 2013-01-15 | Pierre L. Beaulieu | Viral polymerase inhibitors |
| AR068756A1 (es) * | 2007-10-10 | 2009-12-02 | Novartis Ag | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c |
| CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| US7964560B2 (en) * | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| JP2012514605A (ja) | 2009-01-07 | 2012-06-28 | サイネクシス，インコーポレーテッド | Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体 |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| JP2012528195A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物 |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| AU2010341537A1 (en) | 2009-12-22 | 2012-08-09 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases |
| EP2545060B1 (en) | 2010-03-09 | 2015-11-25 | Merck Sharp & Dohme Corp. | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
| AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| EA036995B1 (ru) * | 2015-02-13 | 2021-01-25 | Оксфорд Драг Дизайн Лимитед | НОВЫЕ N-АЦИЛАРИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ АМИНОАЦИЛ-тРНК СИНТЕТАЗЫ |
| WO2017165822A1 (en) | 2016-03-24 | 2017-09-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| JP2023533016A (ja) | 2020-07-11 | 2023-08-01 | ファイザー・インク | 抗ウイルス性ヘテロアリールケトン誘導体 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02500880A (ja) | 1987-11-18 | 1990-03-29 | カイロン コーポレイション | Ｎａｎｂｖの診断用薬およびワクチン |
| EP0381216B1 (en) | 1989-02-01 | 1995-12-27 | Asahi Glass Company Ltd. | Hydrochlorofluorocarbon azeotropic or azeotropic-like mixture |
| DE69133402T2 (de) | 1990-04-04 | 2004-11-11 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Protease von hepatitis-c-virus |
| EP0639585A1 (en) | 1993-08-20 | 1995-02-22 | Banyu Pharmaceutical Co., Ltd. | Elastase inhibitor |
| JPH07109257A (ja) * | 1993-08-20 | 1995-04-25 | Banyu Pharmaceut Co Ltd | エラスターゼ阻害物質 |
| US5884323A (en) * | 1995-10-13 | 1999-03-16 | 3Com Corporation | Extendible method and apparatus for synchronizing files on two different computer systems |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| KR100509388B1 (ko) | 1996-10-18 | 2005-08-23 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제 |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| ES2240446T3 (es) | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
| AR029903A1 (es) | 2000-04-05 | 2003-07-23 | Schering Corp | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento |
| CN101580536A (zh) | 2000-04-19 | 2009-11-18 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
| KR20030081297A (ko) | 2000-07-21 | 2003-10-17 | 쉐링 코포레이션 | Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드 |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| CA2418199A1 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| DK1385870T3 (da) | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| KR20030091946A (ko) | 2000-12-12 | 2003-12-03 | 쉐링 코포레이션 | Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드 |
| EP1408031A1 (en) | 2002-10-09 | 2004-04-14 | 3 D Gene Pharma | Pyrolidine derivatives useful in treatment of hepatitis C virus infection |
-
2005
- 2005-02-24 AU AU2005219859A patent/AU2005219859A1/en not_active Abandoned
- 2005-02-24 TW TW094105620A patent/TW200536528A/zh unknown
- 2005-02-24 US US11/065,572 patent/US7205330B2/en not_active Expired - Fee Related
- 2005-02-24 EP EP05724112A patent/EP1730165A1/en not_active Withdrawn
- 2005-02-24 JP JP2007500818A patent/JP4745327B2/ja not_active Expired - Fee Related
- 2005-02-24 CN CNA2005800130165A patent/CN1950393A/zh active Pending
- 2005-02-24 CA CA002557322A patent/CA2557322A1/en not_active Abandoned
- 2005-02-24 WO PCT/US2005/006502 patent/WO2005085275A1/en not_active Ceased
- 2005-02-24 KR KR1020067017151A patent/KR20060124725A/ko not_active Ceased
- 2005-02-25 AR ARP050100719A patent/AR047901A1/es unknown
-
2006
- 2006-08-15 IL IL177503A patent/IL177503A0/en unknown
- 2006-08-25 ZA ZA200607134A patent/ZA200607134B/xx unknown
- 2006-12-21 US US11/645,181 patent/US7423058B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007535496A5 (https=) | ||
| JP2007525512A5 (https=) | ||
| JP2007525510A5 (https=) | ||
| JP2007525514A5 (https=) | ||
| JP2007525518A5 (https=) | ||
| JP2008511633A5 (https=) | ||
| JP2004504404A5 (https=) | ||
| RU2006134000A (ru) | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с | |
| RU2404189C2 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита c | |
| RU2006134002A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2006134005A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| JP2005524628A5 (https=) | ||
| RU2006124594A (ru) | Ингибиторы сериновой протеазы ns3/ns4а вируса гепатита с | |
| JP2007525521A5 (https=) | ||
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| JP2004513881A5 (https=) | ||
| JP2007535491A5 (https=) | ||
| JP2005515255A5 (https=) | ||
| JP2007513971A5 (https=) | ||
| JP2007515405A5 (https=) | ||
| EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
| WO2005051410B1 (en) | Hepatitis c virus inhibitors | |
| RU2002129564A (ru) | Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с | |
| JP2003530401A5 (https=) | ||
| DE602004023924D1 (en) | Ease-hemmer |